MAPT and Brain atrophy: Individuals with adAD or sAD can also share clinical characteristics such as mode of onset, type of symptoms, progression, duration details [9, 10], patterns of brain atrophy [11, 12] and connectivity [13], as well as levels of biomarkers for the disease such as CSF biomarker levels of beta-amyloid (Aβ42), total-tau, and phosphorylated tau (p-tau) [14].